Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sharp TherapeuticsTSXV:SHRX 14 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 14/100. Among 704 Biotechnology companies, Sharp Therapeutics ranks worse than 142045.31% on this metric.
The historical rank and industry rank for Sharp Therapeutics's Days Payable or its related term are showing as below:
TSXV:SHRX's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 110.01 * Ranked among companies with meaningful Days Payable only.
Sharp Therapeutics's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
stayed the same
The historical data trend for Sharp Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:SHRX vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Sharp Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sharp Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sharp Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Sharp Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sharp Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sharp Therapeutics (TSXV:SHRX) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sharp Therapeutics and its competitors. According to the industry distribution chart, Sharp Therapeutics ranks #999999 out of 704 companies in the Biotechnology industry.
Is Sharp Therapeutics' Days Payable too high?
Sharp Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Sharp Therapeutics ranks #999999 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sharp Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sharp Therapeutics ranks #999999 out of 704 companies for Days Payable. This places Sharp Therapeutics in the lower half of its industry. The industry median Days Payable is 110.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sharp Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sharp Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Days Payable of 0.00. The current Days Payable is 0.00. Sharp Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
14GF Score
Get the complete analysis for TSXV:SHRX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:SHRX has been successfully added to your 
